| Literature DB >> 29450979 |
Kazuomi Kario1, Sungha Park2, Peera Buranakitjaroen3, Yook-Chin Chia4,5, Chen-Huan Chen6, Romeo Divinagracia7, Satoshi Hoshide1, Jinho Shin8, Saulat Siddique9, Jorge Sison10, Arieska Ann Soenarta11, Guru Prasad Sogunuru12,13, Jam Chin Tay14, Yuda Turana15, Lawrence Wong16, Yuqing Zhang17, Ji-Guang Wang18.
Abstract
Hypertension is an important modifiable cardiovascular risk factor and a leading cause of death throughout Asia. Effective prevention and control of hypertension in the region remain a significant challenge despite the availability of several regional and international guidelines. Out-of-office measurement of blood pressure (BP), including home BP monitoring (HBPM), is an important hypertension management tool. Home BP is better than office BP for predicting cardiovascular risk and HBPM should be considered for all patients with office BP ≥ 130/85 mm Hg. It is important that HBPM is undertaken using a validated device and patients are educated about how to perform HBPM correctly. During antihypertensive therapy, monitoring of home BP control and variability is essential, especially in the morning. This is because HBPM can facilitate the choice of individualized optimal therapy. The evidence and practice points in this document are based on the Hypertension Cardiovascular Outcome Prevention and Evidence (HOPE) Asia Network expert panel consensus recommendations for HBPM in Asia. ©2018 Wiley Periodicals, Inc.Entities:
Keywords: Pfizer; blood pressure control; clinical practice; guidelines; home blood pressure monitoring; hypertension
Mesh:
Substances:
Year: 2018 PMID: 29450979 PMCID: PMC8031139 DOI: 10.1111/jch.13216
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN: 1524-6175 Impact factor: 3.738